search
Back to results

Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer

Primary Purpose

Infertility

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
estrogen
Low Molecular Weight Heparin
hCG
progesterone
Sponsored by
Nanfang Hospital, Southern Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring low molecular weight heparin (LMWH), frozen embryo transfer (FET), pregnancy

Eligibility Criteria

20 Years - 43 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged between 20 to 43 years;
  • Body mass index (BMI) between 19 kg/m2 and 25 kg/m2;
  • At least one good quality D3 embryos for transfer;
  • prepare endometrium by hormone replacement therapy(HRT)protocal;
  • capable of giving informed consent.

Exclusion Criteria:

  • Women or their partner with abnormal chromosome karyotype including chromosome polymorphism;
  • Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicornis), adenomyosis, submucous myoma, intrauterine adhesion;
  • Women who underwent unilateral ovariectomy or with history of ovarian tumor surgery ;
  • infection factors: TORCH virus (including Toxoplasma virus, rubella virus, cytomegalovirus,herpes simplex infection),Chlamydia and Mycoplasma, etc;
  • Endometriosis;
  • Having hydrosalpinx ;
  • Low molecular weight heparin contraindications: thrombocytopenia, hemophilia and other bleeding disorders, liver and kidney dysfunction, with a clear history of heparin allergy or allergic constitution, etc.

Sites / Locations

  • Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

NLMWH-A

LMWH-B

Arm Description

non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin(hCG) 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).

low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin(hCG) 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).

Outcomes

Primary Outcome Measures

Clinical pregnancy rate
The pregnancy rate will be evaluated in patients of each groups 4-6 weeks after embryo transfer.

Secondary Outcome Measures

Implantation rate
Evaluation the implantation rate in patients of each groups 4-6 weeks after frozen embryo transfer
Ongoing pregnancy
Evaluation the ongoing pregnancy by monitoring pregnant bursa and fetal heart through ultrasound in patients of each group 12 weeks after embryo transfer.
miscarriage rate
12 weeks

Full Information

First Posted
April 5, 2017
Last Updated
April 14, 2017
Sponsor
Nanfang Hospital, Southern Medical University
search

1. Study Identification

Unique Protocol Identification Number
NCT03120715
Brief Title
Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer
Official Title
Comparison of Clinical Pregnancy Rates Between Two Protocols, With or Without Low Molecular Weight Heparin Administration Before Frozen Embryo Transfer in Hormonal Replacement Cycles: a Prospective Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Unknown status
Study Start Date
July 1, 2016 (Actual)
Primary Completion Date
June 30, 2017 (Anticipated)
Study Completion Date
September 5, 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Nanfang Hospital, Southern Medical University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Embryo freezing is a technique used commonly to optimize the pregnancy rate in assisted reproduction techniques (ART). Hormone replacement therapy (HRT) regimen is applied to prepare endometrium for frozen embryo transfer (FET) commonly.At present, It is unclear whether preimplantation low molecular weight heparin (LMWH) improves live birth and pregnancy rates in subfertile women undergoing FET. The study is a prospective randomized controlled trial to compare the pregnancy outcomes of FET in hormonal replacement therapy(HRT) cycles with or without LMWH administration before implantation.
Detailed Description
This study is a prospective randomized controlled trial. Patients undergoing FET in Center for Reproductive Medicine of Nanfang Hospital, Southern Medical University are recruited. They are randomly allocated to be prepared for transfer by using HRT cycle, with(low molecular weight heparin-group B(group LMWH-B)) or without( non-low molecular weight heparin-group A(group NLMWH-A)) administration of low molecular weight heparin (LMWH) before frozen embryo transfer (FET). Both groups use the same protocol of HRT-FET. The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.In group NLMWH-A, If the endometrial thickness is greater than 9 mm, human chorionic gonadotropin (hCG)10000 IU will be administered via intramuscular injection. Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3). In group LMWH-B, If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection. And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET. Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3). This study was approved by the medicine ethics committee of Nanfang Hospital.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
low molecular weight heparin (LMWH), frozen embryo transfer (FET), pregnancy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
342 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NLMWH-A
Arm Type
Placebo Comparator
Arm Description
non-low molecular weight heparin-group A(group NLMWH-A).Without administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin(hCG) 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Arm Title
LMWH-B
Arm Type
Experimental
Arm Description
low molecular weight heparin-group B(group LMWH-B).With administration of low molecular weight heparin (LMWH) before FET.The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin(hCG) 10000 IU will be administered via intramuscular injection.on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Intervention Type
Drug
Intervention Name(s)
estrogen
Other Intervention Name(s)
estrodiol
Intervention Description
The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
Intervention Type
Drug
Intervention Name(s)
Low Molecular Weight Heparin
Other Intervention Name(s)
LMWH
Intervention Description
If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Intervention Type
Drug
Intervention Name(s)
hCG
Other Intervention Name(s)
Human Chorionic Gonadotropin
Intervention Description
If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin(hCG) 10000 IU will be administered via intramuscular injection.
Intervention Type
Drug
Intervention Name(s)
progesterone
Intervention Description
on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Primary Outcome Measure Information:
Title
Clinical pregnancy rate
Description
The pregnancy rate will be evaluated in patients of each groups 4-6 weeks after embryo transfer.
Time Frame
4-6 weeks
Secondary Outcome Measure Information:
Title
Implantation rate
Description
Evaluation the implantation rate in patients of each groups 4-6 weeks after frozen embryo transfer
Time Frame
4-6 weeks
Title
Ongoing pregnancy
Description
Evaluation the ongoing pregnancy by monitoring pregnant bursa and fetal heart through ultrasound in patients of each group 12 weeks after embryo transfer.
Time Frame
12 weeks
Title
miscarriage rate
Description
12 weeks
Time Frame
Evaluation the miscarriage rate in patients of each group 12 weeks after embryo transfer.

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
43 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged between 20 to 43 years; Body mass index (BMI) between 19 kg/m2 and 25 kg/m2; At least one good quality D3 embryos for transfer; prepare endometrium by hormone replacement therapy(HRT)protocal; capable of giving informed consent. Exclusion Criteria: Women or their partner with abnormal chromosome karyotype including chromosome polymorphism; Women diagnosed as uterus abnormality: malformed uterus (uterus unicorns, septate uterus, duplex uterus, uterus bicornis), adenomyosis, submucous myoma, intrauterine adhesion; Women who underwent unilateral ovariectomy or with history of ovarian tumor surgery ; infection factors: TORCH virus (including Toxoplasma virus, rubella virus, cytomegalovirus,herpes simplex infection),Chlamydia and Mycoplasma, etc; Endometriosis; Having hydrosalpinx ; Low molecular weight heparin contraindications: thrombocytopenia, hemophilia and other bleeding disorders, liver and kidney dysfunction, with a clear history of heparin allergy or allergic constitution, etc.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xin Chen, M.D, Ph.D
Phone
8620-61641908
Email
zhiduoxinrun@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xin Chen, M.D, Ph.D
Organizational Affiliation
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510515
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xin Chen, M.D, Ph.D
Phone
8620-61641908
Email
zhiduoxinrun@163.com
First Name & Middle Initial & Last Name & Degree
Xin Chen, M.D, Ph.D

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer

We'll reach out to this number within 24 hrs